CClinicalTrials.gg
RecruitingNCT06383026Updated Sep 23, 2025

Individuals on Hormone Therapy Breast Cancer Screening Pilot

An observational study in Breast Cancer, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 30 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Medical College of Wisconsin · Observational

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
30 Years to 75 Years
Sex
All
01

Study summary

This investigation is a prospective breast cancer screening study open to all individuals on hormone therapy. Using a mixed methods approach, the study will 1) gather prospective quantitative breast imaging data in conjunction with hormone therapy and family cancer history and 2) investigate individuals on hormone therapy perceptions and experiences in the breast cancer screening program, and 3) identify individual and systems-level barriers to breast cancer screening.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Mammogram
  • Mammography
  • Breast Cancer Screening
  • Breast Ultrasound
  • Breast Ultrasonography
  • Individuals on Hormone Therapy
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's planned enrollment of 130 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Medical College of Wisconsin is the lead sponsor of 540 studies on the registry; 120 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 56 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals on hormone therapy and breast cancer radiology stakeholders.

Eligibility criteria

Inclusion Criteria for Individuals on Hormone Therapy:

  1. Males 40-75 years of age with a history of ≥9 months of estrogen and/or progesterone hormone therapy.
  2. Females 40-75 years of age with any history of testosterone hormone therapy, with or without cosmetic mastectomy, but have not undergone complete mastectomy.
  3. Persons who have undergone breast cancer screening before can participate.
  4. Individuals who meet criteria for above eligibility and are ≥30-39 years of age with a 1st or 2nd degree family member with breast cancer.
  5. Ability to speak, read, and write in English.
  6. Ability to understand a written informed consent document, and the willingness to sign it.

Inclusion Criteria for Breast Radiology Faculty:

  1. Board-certified radiologist that specializes in breast imaging and are an actively employed faculty member at Froedtert \& the Medical College of Wisconsin (main campus location).
  2. Part of the breast radiology faculty who read both ABUS and MMG of the study participants.
  3. Ability to speak, read, and write in English.
  4. Ability to understand a written informed consent document, and the willingness to sign it.

Inclusion Criteria for Breast Radiology Staff:

  1. Must be either a technician, nurse, or clerical staff that works with the breast radiology team at Froedtert \& the Medical College of Wisconsin (main campus location).
  2. Ability to understand a written informed consent document, and the willingness to sign it.
  3. Ability to speak, read, and write in English.

Exclusion Criteria for Individuals on Hormone Therapy

  1. Females who have undergone or planned to undergo a complete mastectomy.
  2. Females who are post-menopausal on estrogen +/- progesterone hormone therapy since it is a well-established risk for breast cancer).
  3. A personal history of breast cancer or a known pathogenic gene mutation that increases the risk of breast cancer development (e.g., BRCA1/2, etc.) given that well-defined surveillance and screening recommendations exist for these persons.

Exclusion Criteria for Breast Radiology Faculty

  1. Not a board-certified radiologist.
  2. Does not specialize in breast imaging.
  3. Does not read ABUS and MMG and/or has not read imaging for study participants.

Exclusion for Breast Radiology Staff

1. Does not work with the breast radiology team.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No

Groups and cohorts

  • Individuals on Hormone Therapy

    Breast imaging data in the form of standard screening mammography in addition to screening whole breast ultrasound will be gathered and interpretations will follow the standard Breast Imaging Reporting and Data Systems. Insight on the perceptions and experiences of being involved in a breast cancer screening program will be gathered.

    Diagnostic Test: Breast Cancer Screening · Other: Survey/Interview

  • Breast Imaging Stakeholders

    A semi-structure focus group to explore radiology faculty and staff experiences while capturing information on the perceived screening barriers, what support and/or training staff require to ensure patients are treated equitable in the screening process, and areas for providers and healthcare systems to improve breast cancer screening for individuals on hormone therapy.

    Other: Focus Group

Interventions

  • Diagnostic testBreast Cancer Screening

    Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.

  • OtherSurvey/Interview

    A mixed-methods approach including electronic surveys and one on one interviews.

  • OtherFocus Group

    A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for individuals on hormone therapy.

06

What researchers measure

Primary outcomes

  1. Callback and Biopsy Rates after Breast Cancer Screening

    Determine the callback and biopsy rates after screening imaging of the entire individuals on hormone therapy patient cohort who complete breast imaging exams.

    Time frame: 3.5 years

  2. Reflexive Thematic Analysis of the Physical, Cognitive, and Emotional Experience of Breast Cancer Screening in Individuals on Hormone Therapy

    Qualitative data utilized to identify themes around health beliefs, anxiety, and the breast cancer screening experience by describing the physical, cognitive, and emotional experience (perceived seriousness, perceived susceptibility, and anxiety) of individuals on hormone therapy cohort participants who complete surveys or participate in one-on-one interviews.

    Time frame: 3.5 years

  3. Reflexive Thematic Analysis on the Individual & System-Level Barriers to Breast Cancer Screening

    Qualitative date utilized to identify individual and healthcare systems-level barriers to breast cancer screening for individuals on hormone therapy who complete surveys and/or participate in one-on-one interviews and breast imaging faculty and staff who participate in focus groups.

    Time frame: 3.5 years

07

Study locations

1 of 1 sites recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06383026
Lead sponsor
Medical College of Wisconsin
Responsible party
Chandler S Cortina (Associate Professor of Surgery, Medical College of Wisconsin) — Principal investigator
First posted
Apr 25, 2024
Start date
Apr 17, 2024
Primary completion
Dec 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 23, 2025

Study contacts

Chandler S Cortina, MD, MS
Contact
ccortina@mcw.edu
4149551453
Chandler S Cortina, MD, MS
principal investigator · The Medical College of Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion